Your browser doesn't support javascript.
loading
Changing how we risk-categorise in Ramadan: Does the IDF-DAR scoring system achieve the requirements for people with diabetes internationally?
Ghouri, Nazim; Hussain, Sufyan; Ahmed, Syed H; Beshyah, Salem A; Rashid, Rafaqat; Al-Ozairi, Ebaa; Waqar, Salman; Dabhad, Ammarah; Mohammed, Ruzwan.
Afiliação
  • Ghouri N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; Department of Diabetes and Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK. Electronic address: nazim.ghouri@glasgow.ac.uk.
  • Hussain S; Department of Diabetes & Endocrinology, St Thomas' Hospital, London, UK; Department of Diabetes & Endocrinology, King' s College London, UK.
  • Ahmed SH; Department of Endocrinology and Metabolic Medicine, Countess of Chester Hospital NHS Foundation Trust, Chester, UK; School of Medicine, University of Liverpool, Liverpool, UK.
  • Beshyah SA; Mediclinic Airport Road Hospital, Abu Dhabi, United Arab Emirates; Dubai Medical College for Girls, Dubai, United Arab Emirates.
  • Rashid R; Al Balagh Academy, Bradford, UK.
  • Al-Ozairi E; Clinical Research Unit, Dasman Diabetes Institute, Kuwait; Department of Medicine, Faculty of Medicine, Kuwait.
  • Waqar S; Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.
  • Dabhad A; Royal Wolverhampton NHS Trust, UK.
  • Mohammed R; Solas Foundation, Glasgow, UK.
Diabetes Res Clin Pract ; 175: 108835, 2021 May.
Article em En | MEDLINE | ID: mdl-33901626
The IDF-DAR guidance was most recently updated this year. The most notable change is the moving to a scoring system from a tabulated risk categorization to determine and classify the risk of harm from fasting derived from an online survey. This change may be appealing and is welcomed. However, such a system and the methodology underpinning it is not without limitations. This commentary highlights some of these limitations and the associated limited safe options available to individuals with diabetes desiring to fast during Ramadan. Overlooked clinical considerations that deserve formal recognition include the role of technology (aspects relating to glucose monitoring and/or insulin delivery) and previous experience of safe Ramadan fasting. Further, duration of fast (which can almost double in temperate regions from winter to summer) needs greater emphasis. We also advocate separate scoring systems for people with type 1 diabetes and complex type 2 diabetes. The guidance acknowledges fasting is an individual's decision, however the general message needs to be more person-centred and currently only presents a binary approach to fasting - all or nothing choices. We propose and discuss addition options including, trial fasting of voluntary fasts, starting the fast and terminating due to health and/or safety, intermittent fasting and winter fasting.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Automonitorização da Glicemia / Jejum / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Automonitorização da Glicemia / Jejum / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article